このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout

2026年11月19日 更新者:ScandiBio Therapeutics AB

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout

This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Consenting participants will be screened for eligibility (Visit 1; screening) according to study-specific eligibility criteria within 7 days prior to randomisation and start of investigational medicinal product (IMP) administration.

Eligible participants will be randomised on Day 1 (Visit 2) to 4 weeks of twice daily (b.i.d.) oral treatment of either CMA2 or placebo (1:1). The first dose will be administered at the study clinic. The participants will be observed for 2 hours post dose for the development of any allergic reactions or intolerance after taking the first dose.

Visits at the study site will be performed at Day 1 (Visit 2), Day 14 (Visit 4) and Day 28 (Visit 6; end of in study treatment). There will be telephone follow up visits at Day 7 (Visit 3) and Day 21(Visit 5) checking safety, concomitant medications and IMP compliance. A final follow-up visit for safety assessments will be conducted in a subgroup of patients 14 days after the end of treatment (Day 42; Visit 7) during an IMP-free follow-up period to assess safety and concomitant medications.

The following clinical scales will be used to evaluate the effect of CMA2 on uric acid decline, hsCRP and daily life activity: Serum Uric Acid Levels, hsCRP, number of flares according to the GAFFO criteria, HAQ-DI, SF-36, PGA (100 mm).

Plasma samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis.

Optionally, synovial samples will be collected for advanced metabolomics, proteomics, and lipidomics analysis. Optionally, gut and saliva samples will be collected for metagenomics analysis of gut and oral microbiome.

Laboratory and clinical safety parameters will be monitored at pre-specified time-points.

研究の種類

介入

入学 (推定)

336

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Gökhan Gönenli, Uzm. Dr. M.
  • 電話番号:+ 90 532 405 76 82
  • メール:mgonenli@ku.edu.tr

研究連絡先のバックアップ

  • 名前:Müjdat Zeybel, Prof. Dr.
  • 電話番号:+ 90 532 604 83 81
  • メール:mzeybel@ku.edu.tr

研究場所

      • Ankara、トルコ(Türkiye)
        • まだ募集していません
        • Ankara Bilkent City Hospital
        • コンタクト:
          • Hakan Babaoğlu
        • 主任研究者:
          • Hakan Babaoğlu, Assoc. Prof. Dr.
      • Antalya、トルコ(Türkiye)
        • まだ募集していません
        • Alanya Training and Research Hospital
        • コンタクト:
          • Şakir Özgür Keskek
        • 主任研究者:
          • Şakir Özgür Keskek, Prof. Dr.
      • Erzurum、トルコ(Türkiye)
        • まだ募集していません
        • Atatürk University Research Hospital
        • コンタクト:
          • Bülent Albayrak
        • 主任研究者:
          • Bülent Albayrak, Assoc. Prof. Dr.
      • Erzurum、トルコ(Türkiye)
        • まだ募集していません
        • Erzurum City Hospital
        • コンタクト:
          • Kenan Çadırcı
        • 主任研究者:
          • Kenan Çadırcı, Prof. Dr.
      • Eskişehir、トルコ(Türkiye)
        • 募集
        • Eskişehir Osmangazi University Faculty of Medicine Hospital
        • コンタクト:
          • Nazife Şule Bige Yaşar
        • 主任研究者:
          • Nazife Şule Bige Yaşar, Prof. Dr.
      • Istanbul、トルコ(Türkiye)
        • まだ募集していません
        • Göztepe Prof. Dr. Süleyman Yalçın City Hospital
        • コンタクト:
          • Esen Kasapoğlu
        • 主任研究者:
          • Esen Kasapoğlu, Prof. Dr.
      • Istanbul、トルコ(Türkiye)
        • まだ募集していません
        • Istanbul University-Cerrahpaşa Faculty of Medicine Hospital
        • コンタクト:
          • Gülen Hatemi
        • 主任研究者:
          • Gülen Hatemi, Prof. Dr.
      • Istanbul、トルコ(Türkiye)
        • まだ募集していません
        • Kanuni Sultan Süleyman Training and Research Hospital
        • コンタクト:
          • Ozan Cemal İçaçan
        • 主任研究者:
          • Ozan Cemal İçaçan, Specialist. Dr.
      • Istanbul、トルコ(Türkiye)
        • まだ募集していません
        • Kartal Dr. Lütfi Kırdar City Hospital
        • コンタクト:
          • Mehmet Engin Tezcan
        • 主任研究者:
          • Mehmet Engin Tezcan, Specialist. Dr.
      • Istanbul、トルコ(Türkiye)
        • 募集
        • Koç University Hospital
        • コンタクト:
        • 主任研究者:
          • Gökhan Gönenli, Specialist. Dr.
      • Istanbul、トルコ(Türkiye)
        • まだ募集していません
        • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital
        • コンタクト:
          • Kadem Arslan
        • 主任研究者:
          • Kadem Arslan, Assoc. Prof. Dr.
      • Istanbul、トルコ(Türkiye)
        • まだ募集していません
        • Sultan 2nd Abdülhamid Han Training and Research Hospital
        • コンタクト:
          • Memnune Sena Ulu
        • 主任研究者:
          • Memnune Sena Ulu, Prof. Dr.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Men and women ≥ 18 years of age.
  2. Individuals with elevated uric acid blood levels (7 mg/dl) and at least one episode of gout during the last three years.
  3. Diagnosis of gout based on 2015 American College of Rheumatology-European Union League Against Rheumatism (ACR-EULAR) criteria.
  4. Able to give written informed consent for participation in the study by the patient and/or legal representatives.

Exclusion Criteria:

  1. Patients who have received uric acid-lowering therapy with a change in dose within 1 month prior to inclusion.

  2. Acute gout flare within 14 days prior to randomization (i.e., any gouty arthritis episode with pain or swelling that has not fully resolved ≤14 days before randomization). Definition of Resolved (for the eligibility assessment): absence of joint pain at rest and no visible swelling at the previously affected joint(s) for at least 48 hours, and no requirement for escalation of anti-inflammatory therapy within that period.

  3. History of stroke.

  4. History of brain trauma < 14 days.

  5. Uncontrolled diagnosed depression.

  6. Uncontrolled diabetes (HbA1c > 8.4%).

  7. Severe swallowing problems.

  8. PEG-feeding.

  9. Chronic diarrhoea.

  10. Chronic kidney disease with S-creatinine > 1.30 mg/dL.

  11. Estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m2 in the Screening Phase

  12. Active bronchial asthma at the time of screening.

  13. History of phenylketonuria

  14. Known allergy for substances used in the study

  15. Known allergy for strawberry

  16. Known active malignancy

  17. Known active psoriasis

  18. Use of dietary supplements such as vitamins, omega-3 products, or plant stanol/sterol products later than one (1) week prior to inclusion.

  19. Use of anti-microbial agents later than one (1) week prior to inclusion.

  20. Drug and/or alcohol abuse.

  21. Participants considered as inappropriate for this study for any reason (noncompliance etc.) per investigator assessment.

  22. Administration of another new chemical entity (defined as a compound that has not been approved for marketing) or has participated in any other clinical study that included drug treatment with the last administration within 3 months prior to administration of IMP in this study.

  23. Females who are breastfeeding or pregnant at screening (as documented by a positive beta human chorionic gonadotropin [β-hCG] test)

  24. Females of childbearing potential who:

    Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:

    • total abstinence (if it is their preferred and usual lifestyle)
    • an intrauterine device or intrauterine hormone-releasing system (IUS)
    • a contraceptive implant
    • an oral contraceptive (Subject must have been on a stable dose of the same oral contraceptive product for at least 28 days before dosing and must agree to stay on the same dose of the oral contraceptive throughout the study and for 28 days after study drug discontinuation.)
    • have a vasectomized partner with confirmed azoospermia. Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation.

    It is permissible that if a highly effective method of contraception is not appropriate or acceptable to the subject, then the subject must agree to use a medically acceptable method of contraception, ie, double-barrier methods of contraception such as latex or synthetic condom plus diaphragm or cervical/vault cap with spermicide.

    NOTE: Females of childbearing potential must have documented tubal ligation or hysterectomy; or be post-menopausal (defined as 12 months of amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) 25-140 IE/L and estradiol <200 pmol/L is confirmatory]).

  25. Male participants who:

    1. Plan to conceive a child or donate sperm during the study treatment period and for at least 90 days after the last dose of investigational product, or
    2. Are unwilling to use effective contraception during the study and for at least 90 days after the last dose of investigational product.
  26. Currently has secondary hyperuricemia:

1) Lesch-Nyhan syndrome 2) Phosphoribosylpyrophosphate synthetase superactivity 3) Congenital myogenic hyperuricemia 4) Hematopoietic neoplasms (acute leukemia, lymphoma malignant, myeloproliferative disorder, myelodysplastic syndrome, etc) 5) Solid tumors (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer, etc) 6) Non-neoplastic diseases (psoriasis vulgaris, secondary polycythemia, hemolytic anemia) 7) Rhabdomyolysis 8) Hypothyroidism 9) Polycystic kidney 10) Lead poisoning/lead nephropathy 11) Down's syndrome 12) Familial juvenile gouty nephropathy 13) Hyperlactacidemia 14) Glycogen storage disease type 1 27. Participants who are on the following treatment are required to be on a stable dose and same mode of administration for at least 14 days prior to screening and to keep the stable during the study. Participants are not permitted to initiate these drugs within 14 days prior to screening and during the study.

  • Dietary and physical therapy for the underlying disease
  • Drugs or containing compound preparations that potentially affect SUA level:
  • Immunosuppressants (mizoribine, cyclosporin, tacrolimus hydrate)
  • Antituberculous drugs (pyrazinamide, ethambutol hydrochloride)
  • Hyperlipidemia drugs (fenofibrate, atorvastatin, rosuvastatin, pitavastatin)
  • Antihypertensives (losartan potassium)
  • Diuretics (thiazide diuretics, loop diuretics)
  • Sodium-dependent glucose transporter (SGLT) 2 inhibitors
  • Theophylline

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:治療アーム

A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.

プラセボコンパレーター:プラセボ群

As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.
時間枠:4 weeks

Absolute change in serum uric acid levels from baseline to end-of-treatment (4 weeks).

4 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
To evaluate the effect of 4 weeks of CMA2 treatment on patient global assessment (PGA, 100 mm) compared with placebo.
時間枠:4 weeks

Change in Patient Global Assessment (PGA, 100 mm) score from baseline to end-of-treatment. PGA is assessed using a visual analogue scale (VAS) ranging from 0 to 10 or 0 to 100, where higher scores indicate worse disease activity.

4 weeks
To evaluate the effect of 4 weeks of CMA2 treatment on High Sensitivity C-reactive Protein (hsCRP) levels compared with placebo.
時間枠:4 weeks

Percentage change in High Sensitivity C-reactive Protein (hsCRP) levels from baseline to end-of-treatment.

4 weeks
To evaluate the proportion of participants achieving serum uric acid levels < 6 mg/dL.
時間枠:4 weeks

Proportion of patients with a serum uric acid level <6 .0 mg/dL at end-of-treatment.

4 weeks
To evaluate the effect of 2-weeks administration of CMA2 treatment on serum uric acid levels compared with placebo.
時間枠:2 weeks

Change in serum uric acid levels from baseline to 2-weeks.

2 weeks
To evaluate patient adherence to the twice-daily treatment regimen.
時間枠:4 weeks

Percentage of expected twice-daily study drug doses successfully administered, as assessed by sachet counts.

4 weeks
To evaluate the incidence of adverse events (AEs).
時間枠:6 weeks

The percentage of subjects experiencing at least one AE during the study period.

6 weeks
To evaluate the severity of AEs.
時間枠:6 weeks

The incidence of AEs categorized by maximum severity grade.

6 weeks
To evaluate the incidence of serious adverse events (SAEs).
時間枠:6 weeks

The percentage of subjects experiencing at least one SAE during the study period.

6 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Gökhan Gönenli, Uzm. Dr. M.、Koc University Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年11月4日

一次修了 (推定)

2027年2月1日

研究の完了 (推定)

2027年2月1日

試験登録日

最初に提出

2026年10月15日

QC基準を満たした最初の提出物

2026年10月15日

最初の投稿 (実際)

2026年10月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月19日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • SB-GOUT-001

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。